双环[2.2.2]辛烷-2-甲酰氯 | 68569-32-4

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 中文名称: 双环[2.2.2]辛烷-2-甲酰氯
• 英文名称: bicyclo[2.2.2]octan-2-ylcarboxylic acid chloride
• 英文别名: 2-Bicyclo[2.2.2]octanecarbonyl chloride；Bicyclo[2.2.2]octane-2-carbonyl chloride
• CAS: 68569-32-4
• 化学式: C₉H₁₃ClO
• 分子量: 172.655
• InChiKey: KCWIFWCZCINQMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  双环[2.2.2]辛烷-2-甲酰氯 在 盐酸羟胺 、 sodium carbonate 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 生成 Bicyclo<2.2.2>oct-2-ylmethylketonoxim
  参考文献：
  名称：

  Langhals, Heinz; Range, Guenter; Wistuba, Eckehardt, Chemische Berichte, 1981, vol. 114, # 12, p. 3813 - 3830

  摘要：

  DOI：

文献信息

• Pyrrolidine compounds and medicinal utilization thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US06468998B1

  公开（公告）日：2002-10-22

  The present invention provides a pyrrolidine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.

  本发明提供了一种式(I)的吡咯烷化合物，其中每个符号如规范中定义，以及其光学活性化合物和药学上可接受的盐。本发明还提供了一种含有式(I)的化合物、其光学活性化合物或药学上可接受的盐以及药学上可接受的添加剂的药物组合物。本发明的化合物具有血清素2受体拮抗作用，同时具有抑制血小板聚集、改善外周循环和促进泪液分泌的作用。因此，本发明的化合物可以是一种有益的药物，对抗血栓栓塞、干眼症等具有一定效果。
• [EN] BICYCLIC INDOLYL DERIVATIVES AND METHODS OF THEIR USE AS SEROTONERGIC AGENTS<br/>[FR] DERIVES D'INDOLYLE BICYCLIQUES, ET PROCEDES RELATIFS A LEUR UTILISATION COMME AGENTS SEROTONERGIQUES
  申请人：WYETH CORP

  公开号：WO2004111035A1

  公开（公告）日：2004-12-23

  Bicyclic indolyl derivatives and compositions containing such compounds are disclosed. Methods of using the bicyclic indolyl derivatives and compositions containing such composition as serotonergic agents, such as in the treatment of depression and anxiety, are also disclosed. In addition, processes for the preparation of bicyclic indolyl derivatives are disclosed.

  本文披露了双环吲哚衍生物及含有这种化合物的组合物。还披露了使用双环吲哚衍生物和含有这种组合物作为5-羟色胺能药物的方法，例如用于治疗抑郁症和焦虑症。此外，还披露了制备双环吲哚衍生物的过程。
• Cyanothiophenes, their preparation and their use in pharmaceutical compositions
  申请人：Anderskewitz Ralf

  公开号：US20060094764A1

  公开（公告）日：2006-05-04

  The present invention relates to cyanothiophenes of general formula wherein the Rs are defined as in the claims, the tautomers, their stereoisomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly a glugacon receptor-antagonistic activity.

  本发明涉及一般式为的氰基噻吩，其中Rs的定义如权利要求中所述，它们的互变异构体、立体异构体、混合物和盐具有有价值的药理特性，特别是一种胰高血糖素受体拮抗活性。
• PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF
  申请人：Welfide Corporation

  公开号：EP1125922A1

  公开（公告）日：2001-08-22

  The present invention provides a pyrrolidine compound of the formula (I) wherein each symbol is as defined in the specification, an optically active compound thereof and a pharmaceutically acceptable salt thereof. The present invention further provides a pharmaceutical composition containing a compound of the formula (I), an optically active compound thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The compound of the present invention has a serotonin 2 receptor antagonistic action along with a platelet aggregation suppressive action, a peripheral circulation improving action and a lacrimation promoting action. Therefore, the compound of the present invention can be a useful medicine showing effect against thrombotic embolism, dry eye and the like.

  本发明提供了一种式 (I) 的吡咯烷化合物 其中各符号如说明书中所定义，其光学活性化合物及其药学上可接受的盐。本发明进一步提供了含有式（I）化合物、其光学活性化合物或其药学上可接受的盐以及药学上可接受的添加剂的药物组合物。本发明的化合物具有 5-羟色胺 2 受体拮抗作用、血小板聚集抑制作用、外周循环改善作用和流泪促进作用。因此，本发明的化合物可以作为一种有用的药物，对血栓性栓塞、干眼症等具有疗效。
• SAR of a Series of 5,6-Dihydro-(9<i>H</i>)-pyrazolo[3,4-<i>c</i>]-1,2,4-triazolo[4,3-α]pyridines as Potent Inhibitors of Human Eosinophil Phosphodiesterase
  作者：Allen J. Duplantier、Elizabeth L. Bachert、John B. Cheng、Victoria L. Cohan、Teresa H. Jenkinson、Kenneth G. Kraus、Michael W. McKechney、Joann D. Pillar、John W. Watson

  DOI：10.1021/jm060904g

  日期：2007.1.1

  The potency and physical properties of a previously reported 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine series of human eosinophil phosphodiesterase inhibitors were improved by tying the lactam moiety into a triazolo ring. The resulting 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridine series provided nonionizable analogs with melting point properties suitable for micronization. Substitution at the 3-position of the 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridine tricycle led to a 2-thienyl analog, 19 (tofimilast), a potent PDE4 inhibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concentrations up to 152 ng/mL.